Earticle

초록

영어

Foot ulcer is a common skin disorder in diabetic patients worldwide. A number of factors are associated with wound healing impairment in diabetic foot ulcer (DFU), including peripheral neuropathy (PN), peripheral arterial disease (PAD), and infection. Here, we present two cases of chronic and recalcitrant DFU in African diabetic patients with a history of treatment failure in both patients, and right foot toe amputation in one of them, prior to wound management with a topical ointment containing Vernonia amygdalina leaf-derived biomaterial (AMX). Case 1 was a 53-year old male diabetic patient who developed type 2 diabetes mellitus 3 years before, had uncontrolled fasting blood glucose (FBG) level, and underwent toe amputation due to a complicated DFU on his left foot (Type IV, Kobe foot ulcer classification). He received wound care with the use of a topical antiseptic and disinfectant solution (Betadine iodine) once every two days and daily antibiotics, in addition to antidiabetic medication. Given that a second amputation was envisaged, his doctor who knew about our product (AMX) requested a sample in 2019. Case 2 was a 34-year old female diabetic patient who had a long-lasting ulcerative skin wound on her left lower limb for almost 10 years (Type IV class ulcer). She has been using topical Dakin’s solution for wound care. With topical application of AMX, rapid soft tissue regeneration and wound closure was observed after 2 months of treatment in Patient1. On the other hand, a wound closure was observed at day10 of AMX treatment in Patient 2. Blood glucose was controlled thanks to the use of an alga-based phytomedicine (NBF) from our research group as adjuvant antidiabetic therapy. Observations from this case report suggest that AMX, known as skin filaggrin (FLG) and TNF-alpha modulator with antibacterial activity, has a potential to serve as alternative treatment for ulcerative skin disorders.

목차

Abstract
1. Introduction
2. Materials and Methods
2.1. Design, subjects and treatment
2.2. Treatment
2.3. DFU classification
2.4. Ethical consideration
3. Results
3.1. Case 1
3.2. Case 2
4. Discussion
5. Conclusion
References

키워드

저자

• Nlandu R. Ngatu [ Congo-Japan Research Group, D.R. Congo/ Kagawa University Faculty of Medicine, Kagawa, Japan ] Corresponding Author
• Miezi Marie-Nsimba [ Congo-Japan Research Group, D.R. Congo/ Faculty of Pharmaceutical Sciences, University of Kinshasa, Kinshasa, D.R. Congo ]
• Luzitu S. Nangana [ Congo-Japan Research Group, D.R. Congo/ Hopital Kimbanguiste de Kinshasa, Kinshasa, D.R. Congo ]
• Christian-Mapong Wansu [ Congo-Japan Research Group, D.R. Congo/ Division of Health Sciences, Institut Superieur Song-Hwa (ISTS), Kinshasa, D.R. Congo ]
• Nzunzu Jose-Lami [ Congo-Japan Research Group, D.R. Congo/ Faculty of Pharmaceutical Sciences, University of Kinshasa, Kinshasa, D.R. Congo ]

참고문헌

발행기관

간행물

표지보기 관심저널 등록

• 간행물명

  선문효정학술연구회 학술대회 프로시딩

• 간기

  반년간

• 수록기간

  2023~2026

• 십진분류

  KDC 238 DDC 289